tiprankstipranks
Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ:CRVS
US Market
CRVS
Corvus Pharmaceuticals
RESEARCH TOOLSreports
Want to see CRVS full AI Analyst Report?

Corvus Pharmaceuticals (CRVS) Stock News & Sentiment

703 Followers
Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained
8d ago
CRVS
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results
Premium
Company Announcements
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results
9d ago
8K
CRVS
Corvus Pharmaceuticals Announces Board Changes and New Director
Premium
Company Announcements
Corvus Pharmaceuticals Announces Board Changes and New Director
29d ago
8K
CRVS
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
Premium
Company Announcements
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline
2M ago
CRVS
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
Premium
Company Announcements
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million
2M ago
8K
CRVS
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
Premium
Ratings
Corvus Pharmaceuticals: Strengthened Cash Runway and Expanding Soquelitinib Pipeline Underpin Buy Rating and Attractive Risk‑Reward Profile
2M ago
CRVS
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
Premium
Company Announcements
Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market
2M ago
CRVS
More CRVS News >

CRVS News on the Web

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Regeneron (REGN) and Corvus Pharmaceuticals (CRVS)
TipRanks News
Neutral
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
The Motley Fool
Bullish
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (KROS), Jasper Therapeutics (JSPR) and Corvus Pharmaceuticals (CRVS)
TipRanks News
Bullish
Corvus Pharmaceuticals' Soquelitinib Shows Durable Remissions and Safety in Atopic Dermatitis Phase 1 Trial
Market Chameleon
Neutral
Buy Rating Reaffirmed on Corvus as Soquelitinib Data Strengthen Thesis; $27 Price Target Maintained
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Phathom Pharmaceuticals (PHAT) and Corvus Pharmaceuticals (CRVS)
TipRanks News
Bullish
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
CRVS
Sector Average
Media Buzz
This Week4 articles
Weekly Average3.75 articles
News Sentiment
This Week100%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CRVS’s Media Buzz Sentiment?
4 articles about CRVS were published this week. In an average week, 3.75 articles are published.
    What is CRVS’s weekly average amount of articles?
    In an average week, 3.75 articles about CRVS are published.
      What is CRVS’s News Sentiment?
      100% of articles about CRVS were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week